- call +1-201-465-4211
- email sales@mrinsights.biz
Antiviral drugs are a class of medication used specifically for treating viral infections rather than bacterial ones
Scope of the Report:
The worldwide market for Anti-Viral Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
This report focuses on the Anti-Viral Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
F. Hoffmann-La Roche
GlaxoSmithKline
Bristol-Myers-Squibb
AbbVie
Johnson & Johnson
Merck & Co
Aurobindo Pharma
Cipla
Dr Reddy’s
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Nucleotide Polymerase Inhibitor
Reverse Transcriptase Inhibitor
Protease Inhibitor
Market Segment by Applications, can be divided into
HIV
Hepatitis
HSV
Influenza
There are 15 Chapters to deeply display the global Anti-Viral Drugs market.
Chapter 1, to describe Anti-Viral Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Anti-Viral Drugs, with sales, revenue, and price of Anti-Viral Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Anti-Viral Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Anti-Viral Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Anti-Viral Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Anti-Viral Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Nucleotide Polymerase Inhibitor
1.2.2 Reverse Transcriptase Inhibitor
1.2.3 Protease Inhibitor
1.3 Market Analysis by Applications
1.3.1 HIV
1.3.2 Hepatitis
1.3.3 HSV
1.3.4 Influenza
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 F. Hoffmann-La Roche
2.1.1 Business Overview
2.1.2 Anti-Viral Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 F. Hoffmann-La Roche Anti-Viral Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 GlaxoSmithKline
2.2.1 Business Overview
2.2.2 Anti-Viral Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 GlaxoSmithKline Anti-Viral Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Bristol-Myers-Squibb
2.3.1 Business Overview
2.3.2 Anti-Viral Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Bristol-Myers-Squibb Anti-Viral Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 AbbVie
2.4.1 Business Overview
2.4.2 Anti-Viral Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 AbbVie Anti-Viral Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Johnson & Johnson
2.5.1 Business Overview
2.5.2 Anti-Viral Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Johnson & Johnson Anti-Viral Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Merck & Co
2.6.1 Business Overview
2.6.2 Anti-Viral Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Merck & Co Anti-Viral Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Aurobindo Pharma
2.7.1 Business Overview
2.7.2 Anti-Viral Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Aurobindo Pharma Anti-Viral Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Cipla
2.8.1 Business Overview
2.8.2 Anti-Viral Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Cipla Anti-Viral Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Dr Reddy’s
2.9.1 Business Overview
2.9.2 Anti-Viral Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Dr Reddy’s Anti-Viral Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Anti-Viral Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Anti-Viral Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Anti-Viral Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Anti-Viral Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Anti-Viral Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Anti-Viral Drugs Market Analysis by Regions
4.1 Global Anti-Viral Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Anti-Viral Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Anti-Viral Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Anti-Viral Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Anti-Viral Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Anti-Viral Drugs Sales and Growth Rate (2013-2018)
4.5 South America Anti-Viral Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Anti-Viral Drugs Sales and Growth Rate (2013-2018)
5 North America Anti-Viral Drugs by Countries
5.1 North America Anti-Viral Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Anti-Viral Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Anti-Viral Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Anti-Viral Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Anti-Viral Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Anti-Viral Drugs Sales and Growth Rate (2013-2018)
6 Europe Anti-Viral Drugs by Countries
6.1 Europe Anti-Viral Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Anti-Viral Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Anti-Viral Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Anti-Viral Drugs Sales and Growth Rate (2013-2018)
6.3 UK Anti-Viral Drugs Sales and Growth Rate (2013-2018)
6.4 France Anti-Viral Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Anti-Viral Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Anti-Viral Drugs Sales and Growth Rate (2013-2018)
7 Asia-Pacific Anti-Viral Drugs by Countries
7.1 Asia-Pacific Anti-Viral Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Anti-Viral Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Anti-Viral Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Anti-Viral Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Anti-Viral Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Anti-Viral Drugs Sales and Growth Rate (2013-2018)
7.5 India Anti-Viral Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Anti-Viral Drugs Sales and Growth Rate (2013-2018)
8 South America Anti-Viral Drugs by Countries
8.1 South America Anti-Viral Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Anti-Viral Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Anti-Viral Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Anti-Viral Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Anti-Viral Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Anti-Viral Drugs Sales and Growth Rate (2013-2018)
9 Middle East and Africa Anti-Viral Drugs by Countries
9.1 Middle East and Africa Anti-Viral Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Anti-Viral Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Anti-Viral Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Anti-Viral Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Anti-Viral Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Anti-Viral Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Anti-Viral Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Anti-Viral Drugs Sales and Growth Rate (2013-2018)
10 Global Anti-Viral Drugs Market Segment by Type
10.1 Global Anti-Viral Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Anti-Viral Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Anti-Viral Drugs Revenue and Market Share by Type (2013-2018)
10.2 Nucleotide Polymerase Inhibitor Sales Growth and Price
10.2.1 Global Nucleotide Polymerase Inhibitor Sales Growth (2013-2018)
10.2.2 Global Nucleotide Polymerase Inhibitor Price (2013-2018)
10.3 Reverse Transcriptase Inhibitor Sales Growth and Price
10.3.1 Global Reverse Transcriptase Inhibitor Sales Growth (2013-2018)
10.3.2 Global Reverse Transcriptase Inhibitor Price (2013-2018)
10.4 Protease Inhibitor Sales Growth and Price
10.4.1 Global Protease Inhibitor Sales Growth (2013-2018)
10.4.2 Global Protease Inhibitor Price (2013-2018)
11 Global Anti-Viral Drugs Market Segment by Application
11.1 Global Anti-Viral Drugs Sales Market Share by Application (2013-2018)
11.2 HIV Sales Growth (2013-2018)
11.3 Hepatitis Sales Growth (2013-2018)
11.4 HSV Sales Growth (2013-2018)
11.5 Influenza Sales Growth (2013-2018)
12 Anti-Viral Drugs Market Forecast (2018-2023)
12.1 Global Anti-Viral Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Anti-Viral Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Anti-Viral Drugs Market Forecast (2018-2023)
12.2.2 Europe Anti-Viral Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Anti-Viral Drugs Market Forecast (2018-2023)
12.2.4 South America Anti-Viral Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Anti-Viral Drugs Market Forecast (2018-2023)
12.3 Anti-Viral Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Anti-Viral Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Anti-Viral Drugs Market Share Forecast by Type (2018-2023)
12.4 Anti-Viral Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Anti-Viral Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Anti-Viral Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Anti-Viral Drugs Picture
Table Product Specifications of Anti-Viral Drugs
Figure Global Sales Market Share of Anti-Viral Drugs by Types in 2017
Table An
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
